Letrozole
- Generic Name
- Letrozole
- Brand Names
- Femara, Kisqali Femara Co-pack
- Drug Type
- Small Molecule
- Chemical Formula
- C17H11N5
- CAS Number
- 112809-51-5
- Unique Ingredient Identifier
- 7LKK855W8I
- Background
Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990. It is a third generation aromatase inhibitor like exemestane and anastrozole, meaning it does not significantly affect cortisol, aldosterone, and thyroxine.
Letrozole was granted FDA approval on 25 July 1997.
- Indication
Letrozole is indicated to treat postmenopausal women with hormone receptor (HR) positive early breast cancer, postmenopausal women with early breast cancer who have periviously been treated with tamoxifen, and postmenopausal women with HR+ or unknown advanced breast cancer. Letrozole, given with ribociclib, is indicated to treat pre, peri, and postmenopausal...
- Associated Conditions
- Advanced Breast Cancer, Anovulatory cycle, Epithelial Ovarian Cancer, HR+, HER2-, Advanced Breast Cancer, Stage I Breast Cancer, Metastatic HR + HER2 - breast cancer
- Associated Therapies
- -
Mid-luteal Phase Synchronization of Ovarian Folliculogenesis in Women
- Conditions
- Interventions
- First Posted Date
- 2007-11-29
- Last Posted Date
- 2010-04-22
- Lead Sponsor
- University of Saskatchewan
- Target Recruit Count
- 41
- Registration Number
- NCT00565240
- Locations
- 🇨🇦
Royal University Hospital, Saskatoon, Saskatchewan, Canada
Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer
- First Posted Date
- 2007-11-04
- Last Posted Date
- 2020-03-11
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 4884
- Registration Number
- NCT00553410
- Locations
- 🇨🇭
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
🇦🇹Innsbruck Universitaetsklinik, Innsbruck, Austria
🇺🇸Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Intermittent Letrozole Therapy in Postmenopausal Women With Metastatic Breast Cancer
- First Posted Date
- 2007-10-26
- Last Posted Date
- 2017-03-22
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 3
- Registration Number
- NCT00549822
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal Women
- Conditions
- Interventions
- First Posted Date
- 2007-10-17
- Last Posted Date
- 2023-03-31
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 380
- Registration Number
- NCT00545077
- Locations
- 🇩🇪
Universitätsklinikum Essen, Essen, Germany
🇩🇪Klinikum Bayreuth, Bayreuth, Germany
🇩🇪Universitätsklinikum Charité, Berlin, Germany
Study of Anastrozole, Letrozole, or Exemestane With or Without Tamoxifen in Treating Postmenopausal Women With Hormone-Responsive Breast Cancer That Has Been Completely Removed By Surgery
- Conditions
- Interventions
- First Posted Date
- 2007-10-08
- Last Posted Date
- 2020-02-07
- Lead Sponsor
- Gruppo Italiano Mammella (GIM)
- Target Recruit Count
- 3697
- Registration Number
- NCT00541086
- Locations
- 🇮🇹
Federico II University Medical School, Naples, Italy
🇮🇹Istituto Nazionale per lo Studio e la Cura dei Tumori, Naples, Italy
🇮🇹Seconda Universita di Napoli, Naples, Italy
Optimal Duration of Pre-operative Treatment With Letrozole and to Correlate Clinical Efficacy With Appropriate Surrogate Markers
- First Posted Date
- 2007-09-26
- Last Posted Date
- 2017-09-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 35
- Registration Number
- NCT00535418
Dehydroepiandrosterone (DHEA) and Letrozole in Treating Patients With Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2007-08-15
- Last Posted Date
- 2012-07-24
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 6
- Registration Number
- NCT00516542
- Locations
- 🇺🇸
Knight Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States
Letrozole in Patients With Ovarian Tumors
- Conditions
- Interventions
- First Posted Date
- 2007-07-23
- Last Posted Date
- 2012-04-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 16
- Registration Number
- NCT00505661
- Locations
- 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States
Letrozole and Goserelin or Leuprolide in Treating Premenopausal Estrogen Receptor-Positive Patients With Stage IV Breast Cancer
- Conditions
- First Posted Date
- 2007-07-11
- Last Posted Date
- 2013-05-09
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 1
- Registration Number
- NCT00498901
- Locations
- 🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸University Cancer Center at University of Washington Medical Center, Seattle, Washington, United States
PhII Neo-Adjuvant Letrozole & Lapatinib in Pts w/HER2+ & Hormone Receptor+ Operable Breast CA SPORE
- Conditions
- Interventions
- First Posted Date
- 2007-07-11
- Last Posted Date
- 2012-08-10
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT00499681
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center - Cool Springs, Nashville, Tennessee, United States
🇺🇸Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Vanderbilt-Ingram Cancer Center at Franklin, Nashville, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.